AI Research for Pharma: Pressure-Test Positioning Before Launch
On this page
A pharma launch lead needs to decide which positioning, advisory questions, patient-journey assumptions, and access arguments warrant further work. Recruitment, schedules, permissions, and therapeutic-area coverage can constrain the study. Sermo's advisory-board guide, updated August 2026, describes specialty-dependent compensation and flexible meeting arrangements; it does not establish a universal months-long timetable or a price for your project.
Define the launch unknown and the evidence needed before locking the strategy. Direct HCP, patient, or payer work may begin first. A modeled comparison can be an optional preparation stage where its population and task coverage are supported.
Which reaction is worth testing before you commit
For a message decision, specify the audience, approved content, comparator, assignment, and measured response. For clinical performance or coverage policy, use the relevant clinical, regulatory, or payer evidence. A modeled objection can suggest a question; it cannot establish what prescribers or committees will do.
A scoped Subconscious study may compare proposed messages using generated responses. Check population coverage, inputs, and matched validation for the therapeutic area. The aggregate evidence record does not establish prescriber, patient, or committee fidelity for this project. Generated results are conditional modeled evidence; communication testing is separate from clinical substantiation.
How does drug launch positioning research work?
Launch research can combine HCP qualitative work, message testing, conjoint, and awareness or usage studies, with iteration between rounds. A modeled pilot may offer another route to refining stimuli, subject to its scope and coverage. Compare actual turnaround, adaptation, and evidence quality with the available human designs.
A randomized comparison of efficacy-led, safety-led, or convenience-led approved messages can estimate a contrast on a defined endpoint such as comprehension or stated preference. For generated respondents, that estimate is conditional on the model. It does not establish prescribing, patient outcomes, or a cause of any individual's decision.
Why is real KOL time so scarce and valuable?
Advisory work also raises conflict-of-interest questions. Ray Moynihan's 2008 BMJ article discussed the tension between expert independence and sponsor payments. That historical analysis is relevant to disclosure and relationships, rather than a current compensation benchmark.
For current procurement, confirm specialty, geography, task, permitted engagement, and compensation with the appropriate owners.
For KOL preparation, a model can suggest possible objections or discussion-guide variants. Publication records or stated positions may inform permitted inputs, but confirm availability, provenance, and use rights. Public professional facts do not validate a generated person's unseen response. Attribute source facts accurately and never present simulated speech as a real named KOL's view.
Patient journey mapping
Patient-journey questions need actual patient interviews, observation, or appropriate records, especially where rare disease and longitudinal experience limit coverage. Generated narratives can suggest probes but cannot reveal which stages actually matter to patients.
Use a modeled comparison, if suitable, to explore how a defined description or message is understood. Keep poorly covered stages and unexpected patient hypotheses for direct work. A simulated weak response is not a sufficient reason to cut that stage's interview budget.
Why is formulary committee research so hard?
Payer interviews, mock P&T exercises, and available coverage-policy records can clarify access questions. A modeled reviewer can suggest objections to a specified argument, but cannot reproduce a committee's deliberation or decision without independent evidence. Obtain actual payer expertise for clinical, economic, and policy assumptions.
| Launch stage | Traditional research | Where a causal experiment adds a comparison |
|---|---|---|
| Pre-launch | HCP discovery and message testing | Optional generated-message screen; confirm therapeutic-area coverage |
| KOL preparation | Advisory work with appropriate disclosure | Suggested questions or variants, not attributed KOL responses |
| Patient journey | Patient interviews, observation, and records | Hypotheses for probes; no budget exclusions based solely on simulation |
| Formulary access | Payer research and policy evidence | Possible objections; no claim to predict a committee vote |
Use the comparison for its measured response. Record uncertainty, unsupported audience assumptions, and the independent evidence needed before choosing a launch or access action.
Which review is required before claims are used?
A modeled result can support preparation under its assumptions. It does not establish clinical efficacy, safety, patient outcomes, or a payer decision. Human message testing also does not establish those claims. Keep source clinical facts, generated responses, and human research results visibly distinct.
Before promotional use, the medical, legal, and regulatory owners should assess the actual communication against the applicable evidence and approved labeling. FDA's Office of Prescription Drug Promotion reviews prescription-drug promotion for truthful, balanced, nonmisleading communication. Human validation can assess comprehension or preference, but does not replace clinical substantiation. Document any audience, instrument, or endpoint changes between modeled and human work.
Bring one launch or access decision, its target population, allowed content, comparator, and endpoint to a study discussion. Confirm coverage, data permissions, independent validation, and claim-review responsibilities before collection.